Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday in its ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic ...

After falling just short of the $20 billion figure in annual sales for three straight years, AbbVie's Humira finally topped the elusive mark—and did it by a comfortable margin—generating $20.7 billion ...

Skyrizi (risankizumab-rzaa) and Humira (adalimumab) are prescription drugs that treat conditions such as psoriatic arthritis. The cost of both drugs depends on several factors. Skyrizi and Humira are ...

The pharmaceutical industry is known to defend its big prices for drugs by citing the risky nature of drug development and the regularly touted study showing it costs more than $2.5 billion to ...

You might call it the Swiss army knife of pharmaceutical drugs. Since it hit the market in 2002 to treat rheumatoid arthritis, Humira has racked up one governmental approval after another to treat ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...